- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04971083
Patient-centered Nutrition Care II: An E-health Supported Symptom Based Nutrition Intervention (PaCC II)
Intervention Phase: Patient-centered Nutrition Care (PaCC II)
Study Overview
Status
Intervention / Treatment
Detailed Description
Primary Endpoint:
Nutrition care, augmented with E-Health tools containing tailored behavioural tipps enable the maintenance of overall nutrition status 12 weeks from baseline as measured with the Scored Patient-Generated Subjective Global Assessment. .
Secondary Endpoints will include:
- difference in the two arms in % weight loss
- difference in the number and severity of further Patient Reported nutrition relation symptoms according to Patient Reported- Common Toxicity Criteria for adverse events (PRO-CTCAE™) developed by the Division of Cancer Control and Population Sciences in the National Cancer Institute Version date: 2/25/2019
- change in Quality of Life as measured by Functional Assessment of Cancer Therapy - General questionnaire
- improvement of nutrition status
- change in the % of estimated energy intake achieved
- difference of the number of discontinuations or delay in therapy
- difference of Glasgow Prognostic Score (only when C-reactive protein und Albumin are available in the routine blood draw)
- change in Distress status
Study Design:
This mono-centric prospective randomized study is designed to test the hypothesis of a causal pathway between nutritional interventions containing tailored behavioural tipps augmented with E-health tools on predefined outcomes (nutrition status, weight loss, extent and severity of nutrition related symptom burden (NRSB), distress status QoL) The study will utilize E-Health tools to ensure regular and early identification of potential nutrition related symptoms on the part of both the patient and the clinician. Within this framework, the trial will include cancer patients with tumors in the GI tract undergoing chemo and/or immune therapy who will receive therapy for a minimum of six weeks after recruitment.
Study Methods:
Control (CG): receives Usual Care (Nutrition intervention according to house standards: Nutrition Risk Score ≥ 3, or patient, or clinician request). Additionally, patients will record their energy intake, weight, general state of being, symptoms, and distress status in the Electronic Health Platform (EHIP) and have to ability to print and share this documentation with their health care providers (HCP) at their own discretion.
Intervention Group (IG): analog to the control group, patients record their energy intake, weight, general state of being, symptoms, and distress status in the Electronic Health Platform (EHIP). A built-in automated analysis will provide patient-tailored nutrition recommendations. Dependent on the severity of the NRSB recorded, they are, for example, provided with detailed written nutrition information and cooking recipes aimed at and/or asked to discuss their symptoms with their dietitian, physician, or, if necessary, to seek immediate medical care. As in the control group, patients will also have the ability to print and share this documentation with their HCP at their own discretion.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Julian W Holch, PD, MD
- Phone Number: 089 4400 75246
- Email: Julian.Holch@med.uni-muenchen.de
Study Contact Backup
- Name: Nicole Erickson, M.Sc.
- Phone Number: 089 4400 75246
- Email: nicole.erickson@med.uni-muenchen.de
Study Locations
-
-
Barvaria
-
Munich, Barvaria, Germany, 81377
- Recruiting
- Comprehensive Cancer Center Ludwig Maximilian University Munich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cancer patients with tumors in the GI tract undergoing chemo and/or Immunotherapy and are primarily treated on an outpatient basis
- ≥ 18 years
- Life expectancy ≥ 6 months
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
- Open for, and ability to use, of E-Health platforms (own and uses one or more electronic devices with access to internet)
- Able to take 75% of foods orally
- Valid declaration of consent to participate in the study
Exclusion Criteria:
- Cancer patients with other diagnoses or who are not receiving chemo or Immunotherapy or undergoing intensive therapy requiring longer in-patient stays (e.g: Intensive Care Patients)
- ≤ 18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≥3
- More than 75% of Energy intake is not taken oral but instead via enteral or parenteral route.
- Operation planned during the course of the Study (next 3 months)
- Patient who do provide not or withdraw their consent
- Not open or willing to use E-Health tools
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Usual Care
Control (CG): receives Usual Care. Observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion. Inflammation status will be recorded when data from routine blood draws is available |
|
Active Comparator: Intervention Group
Intervention Group (IG): The intervention consists of a built-in automated analysis that provide patient-tailored nutrition recommendations and behavioural tipps. Described in detail this means that dependent on the severity of the nutrition related symptom burden (NRSB) recorded, the patients in the intervention group only are, for example provided with detailed written nutrition information and cooking recipes and/or asked to discuss the symptoms with their health care provider, dietitian, and/or physician, or even asked to seek immediate medical care. Analog to the control group, observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion. Inflammation status will be recorded when data from routine blood draws is available |
This study is designed to provide patients a tool with which they can record the nutrition related symptom burden (NRSB) they are experiencing in real time.
A pre-defined algorithm then provides them with tailored nutrition information and behavioural tipps based on the severity grade of the symptom recorded.
The aim is to increase the chances that such symptoms, when clinically relevant, are addressed in a timely matter and thus the nutrition status is stabilized.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stabilization of patient-reported nutrition nutrition status
Time Frame: 12 weeks from baseline
|
A automated analysis embedded in the E-health tool will provide patient-tailored nutrition information and behavior advice aimed at stabilizing or improving nutrition status.
Nutrition status will be measured using the scored Patient-Generated Subjective Global Assessment (scale of 1-36) whereas a higher score indicates a declining nutrition status
|
12 weeks from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and severity of patient-reported nutrition related symptoms between the groups
Time Frame: 12 weeks from baseline
|
Difference of the number and severity of patient-reported nutrition related symptoms according to Patient Reported- Common Toxicity Criteria for adverse events (PRO-CTCAE™) developed by the Division of Cancer Control and Population Sciences in the National Cancer Institute Version date: 2/25/2019.
13 Symptoms will be measured for frequency and severity.
|
12 weeks from baseline
|
Weight change
Time Frame: 12 weeks from baseline
|
Difference in percent of weight change between the groups
|
12 weeks from baseline
|
Quality of life improvement
Time Frame: 12 weeks from baseline
|
Improvement of Quality of life as measured by the Functional Assessment of Cancer Therapy - General (FAKT-G) questionnaire.
According the scale of 0-108 the higher the score, the better the QOL.
|
12 weeks from baseline
|
Improvement of nutrition intake
Time Frame: 12 weeks from baseline
|
% of estimated energy intake
|
12 weeks from baseline
|
Discontinuations or delay in therapy reduction
Time Frame: 12 weeks from baseline
|
no. of discontinuations or delay in therapy
|
12 weeks from baseline
|
Inflammation status
Time Frame: 12 weeks from baseline
|
change in Glasgow Prognostic Score on a scale of 0-2 (only when C-reactive Protein und Albumin are available in the routine blood draw).
A higher score indicates more inflammation
|
12 weeks from baseline
|
Distress status
Time Frame: 12 weeks from baseline
|
change in Distress state measured by Distress Thermometer on a scale of 1-10.
A higher the score indicates more Distress
|
12 weeks from baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Nicole Erickson, M.Sc., CCC Ludwig Maximillian University Munich
- Principal Investigator: Julian Holch, PD, MD, CCC Ludwig Maximillian University Munich
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PaCC II
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaActive, not recruitingImprove Quality of LifeItaly
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
Region VästmanlandUnknownHealth Related Quality of Life
Clinical Trials on Intervention Group
-
Muğla Sıtkı Koçman UniversityNot yet recruiting
-
University of LiegeCentre Hospitalier Universitaire de Liege; Bial Foundation; FNRS (Télévie); Fondation...RecruitingPain | Cancer | Fatigue | Cognitive Impairment | Sleep Disturbance | Distress, EmotionalBelgium
-
Hospital de Clinicas de Porto AlegreUnknown
-
University of California, San FranciscoNational Cancer Institute (NCI); Cancer Prevention Institute of CaliforniaCompletedHereditary Breast and Ovarian Cancer Syndrome
-
University of Sao PauloCompletedAnxiety | Self Esteem
-
Haute Ecole de Santé VaudCompletedArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipSwitzerland
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases
-
University of OxfordOxford Brookes UniversityRecruitingOverweight/Obesity, AdolescentUnited Kingdom
-
Azienda Ospedaliero-Universitaria CareggiRecruiting
-
Vitalija StonkuvienėRecruitingFrailty SyndromeLithuania